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Study design
This was a single-blinded, placebo-controlled, fi xed sequence study designed to examine the effects of torcetrapib on plasma lipoproteins and lipoprotein metabolism in subjects with low HDL cholesterol. A total of 19 subjects were enrolled, with nine subjects studied while receiving atorvastatin treatment throughout the study. Both cohorts included one female subject, one subject with the 2/3 apoE genotype, and one subject with the 3/4 apoE genotype. All subjects were similar with respect to age and body mass index, but, as expected, the levels of LDL cholesterol and total apoB at randomization were lower in the atorvastatin cohort ( Table 1 ) . A detailed description of the study has been reported previously ( 15 ) . Briefl y, the study consisted of an introductory period lasting 2 to 4 weeks, during which the subjects were screened and, if necessary (subjects with a LDL cholesterol >160 mg/dl; n = 9), received atorvastatin 20 mg once daily throughout the study. All subjects were placed on placebo for 4 weeks, followed by torcetrapib 120 mg once daily for an additional 4 weeks. Six of the 10 subjects not taking atorvastatin also participated in a third phase, in which they were given torcetrapib 120 mg twice daily for 4 weeks. Only 9 of the 10 subjects not on atorvastatin were studied during the torcetrapib 120 mg once daily phase, due to unsatisfactory data (see below). There was no washout period between the phases.
At the end of each 4-week treatment period, the subjects underwent a primed-constant infusion of deuterated leucine, under constantly fed conditions, to determine the kinetics of apoB-48. As described previously ( 19 ) , the subjects were fed hourly for 20 h with small identical meals (15% calories as protein, 49% as carbohydrate, 36% as fat; 180 mg cholesterol/1,000 kcal) starting 5 h before and continuing throughout the infusion. All plasma and TRL lipid and apolipoprotein levels have been shown in previous studies to be stable by the start of the infusion period and not to change signifi cantly throughout the infusion period ( 19, 20 ) . At 11 AM (0 h), [5,5,5-D 3 ]L-leucine (C/D/N Isotopes, PointeClaire, Quebec) 10 mol/kg body weight was injected intravenously as a bolus over 1 min and then by continuous infusion for 15 h at a rate of 10 mol/kg body weight/h. Blood samples were collected into tubes containing EDTA (0.15%) just before the infusion (0 h) and at 30, 35 , and 45 min and at 1, 1.5, 2, 3, 4, 6, 9, 12, 14, and 15 h during the infusion. The samples were placed on ice immediately. The TRL (d <1.006 g/ml) particles were isolated from fresh plasma by density ultracentrifugation ( 21 ) , divided into aliquots for TRL apoB measurement or isolation, and stored at Ϫ 80°C for no more than 3 years before analysis.
Apolipoprotein isotopic enrichment and kinetic analysis
As described previously ( 22 ) , TRL proteins were separated by gradient SDS-PAGE and transferred to a Westran S polyvinylidene difl uoride membrane (GE Life Sciences, Piscataway, NJ) using a Tris-glycine-methanol system. ApoB-48 bands were visualized by Coomassie blue R-250, excised from the membrane, and hydrolyzed with 12 N HCl at 110°C for 24 h. Amino acids were converted to n-propyl ester and heptafl uorobutyramide derivatives and analyzed for isotopic enrichment by electron capture negative chemical ionization gas chromatography-mass spectrometry. A capillary column coated with DX-4 stationary phase was used to separate leucine from its isomer isoleucine. Selected ion monitoring at m/z 349 (derivatized leucine -HF)
Ϫ and m/z 352 (derivatized D 3 -leucine -HF) Ϫ was used to determine the areas under the chromatographic peaks for each ion. Moles percent enrichment (D 3 -leucine/[D 3 -leucine + leucine]) for each sample was calculated from the area under the curve and converted to a tracer-tracee ratio (percent) to account for the isotopic enrichment of the D 3 -leucine tracer ( 23 ) .
the formation of chylomicron remnants. Unlike apoB-100, apoB-48 does not contain the LDL receptor-binding domain, and apoB-48-containing remnants are taken up by hepatic receptors that recognize apoE ( 10, 11 ) . The metabolism of TRL is linked to that of HDL through the activity of plasma enzymes and transport proteins. Cholesteryl ester transfer protein (CETP) plays a crucial role by mediating the bidirectional net exchange of cholesteryl ester (CE) in HDL for TG in the apoB-containing lipoproteins.
CETP activity is increased under postprandial conditions, and in dyslipidemia it can contribute signifi cantly to an enhanced cholesterol burden of the atherogenic apoBcontaining lipoproteins. In familial combined hyperlipidemia, Guerin and colleagues ( 12 ) have reported that the increased number of postprandial chylomicrons and large VLDL-1 acceptor particles, combined with the postprandial targeting of VLDL-1 as the preferred TRL acceptor of CE from HDL, results in enhanced CE transfer. Increased CETP activity, in turn, causes the accumulation of a population of CE-enriched atherogenic remnant particles containing apoB-48 and apoE ( 12 ) . It is well known that plasma TG and HDL cholesterol levels are inversely related ( 13 ) . One explanation for this potentially atherogenic relationship is that, in patients with elevated plasma TG levels, the CE content in HDL decreases as a consequence of enhanced CETP activity. Inhibition of CETP activity may, therefore, constitute a therapeutic approach that not only raises HDL cholesterol but also attenuates the atherogenic profi le of apoB-48-containing lipoproteins ( 12, 14 ) .
We have reported previously that partial inhibition of CETP activity with torcetrapib signifi cantly increased plasma concentrations of HDL cholesterol, apoA-I, and large HDL particles and decreased LDL cholesterol, apoB, and small dense LDL concentrations in subjects with low baseline levels of HDL cholesterol (15) (16) (17) (18) . The HDL-raising effects mediated by torcetrapib in these subjects were associated with signifi cant delays in the catabolism of HDL apoA-I, as well as signifi cant increases in the clearance of VLDL apoB-100 and apoE. The aim of the present study was to determine the effects of torcetrapib-mediated inhibition of CETP on apoB-48 metabolism and TRL composition in the same subjects.
METHODS

Subjects
The subjects in this study were recruited at Tufts Medical Center (Boston, MA) and the University of Pennsylvania (Philadelphia, PA). Subjects were eligible if they met the following criteria: age 18 to 70 years, HDL cholesterol <40 mg/dl, TG <400 mg/dl, LDL cholesterol <160 mg/dl, and body mass index between 18 and 35 kg/m 2 . Subjects having a LDL cholesterol of <160 mg/dl while on a stable dose of atorvastatin 20 mg once daily were considered for the atorvastatin arm of the study, provided they met the other criteria. Exclusion criteria have been described previously in detail ( 15 ) . The study protocol was approved by the human investigation review committee of each institution. Informed, written consent was obtained from each study subject. 
Statistical analysis
The SAS System for Windows (release 9.2; SAS Institute) was used for statistical analysis. Signifi cant differences in the means between placebo and torcetrapib phases within a given group were assessed by paired t -tests, whereas two-independent sample t-tests were used to detect differences between the nonatorvastatin and atorvastatin cohorts. A logarithmic transformation was applied to the data not normally distributed before formal analysis. The percent change relative to placebo was calculated on an individual basis and summarized descriptively by cohort. Spearman correlations were used in the correlation analyses. All data in the text, tables, and graphs are presented in the original scale of measurement as means ± SEM. P < 0.05 was considered signifi cant.
RESULTS
Effects of torcetrapib on nonfasting concentrations of apoB-48 and TRL lipids
As reported previously ( 15 ) , partial inhibition of CETP activity with torcetrapib signifi cantly decreased fasting plasma concentrations of total apoB when the drug was given as monotherapy or in combination with atorvastatin. Torcetrapib also had notable effects on nonfasting concentrations of TRL apoB-48 ( Fig. 1 ; see supplementary data for the effects on apoB-100, apoA-I, apoA-II, and apoE concentrations). Relative to placebo, TRL apoB-48 levels were decreased signifi cantly, by 49 ± 9% (mean ± SEM; P = 0.007) in the nonatorvastatin 120 mg once daily group (from 0.47 ± 0.10 to 0.23 ± 0.08 mg/dl) and by 31 ± 6% ( P = 0.009) in the nonatorvastatin 120 mg twice daily group (from 0.57 ± 0.15 to 0.40 ± 0.12 mg/dl). No signifi cant decrease in TRL apoB-48 levels was observed in the atorvastatin cohort.
The effects of torcetrapib on nonfasting lipid concentrations are shown in Table 2 . Relative to placebo, torcetrapib decreased plasma TG levels by 21 ± 8% ( P = 0.04) in the once daily cohort, by 7 ± 8% ( P not signifi cant) in the The SAAM II program (University of Washington, Seattle, WA) was used to determine the fractional catabolic rate (FCR) of apoB-48 using a previously described multicompartmental model ( 22, 24 ) . The model assumed a constant enrichment of the precursor pool, as has been demonstrated in metabolic studies using a primed-constant infusion to administer labeled leucine ( 22, 24, 25 ) . Determination of the FCR is independent of the level of precursor enrichment. ApoB-48 concentration was maintained constant over the 15 h infusion period. The production rate (PR) was computed as the product of the FCR and the pool size (PS), which equals the plasma concentration multiplied by plasma volume, estimated as 4.5% of body weight in kilograms.
One subject in the nonatorvastatin arm who also participated in the torcetrapib 120 mg twice daily phase had unsatisfactory enrichment data for the torcetrapib 120 mg once daily phase. The tracer data for the unsatisfactory phase were not modeled, and the data for this subject were included only in the torcetrapib 120 mg twice daily subset analysis.
Quantitation of apoB-48 and TRL lipids
Lipid and apolipoprotein levels were measured in fasting and nonfasting plasma samples as previously reported (15) (16) (17) (18) . Plasma levels of total cholesterol (TC) and TG were measured by automated enzymatic assays standardized through the Centers for Disease Control (Atlanta, GA) ( 26 ) . The lipid composition of the nonfasting TRL fraction isolated from fresh plasma by density ultracentrifugation and stored at Ϫ 80°C was measured using enzymatic reagents for total and free cholesterol and TG (Wako Chemicals, USA); CE concentration was calculated as the difference between total and free cholesterol. To determine the nonfasting concentration of apoB-48 in TRL (containing both chylomicrons and VLDL), the concentration of total apoB in TRL was measured with a noncompetitive ELISA using previously separated frozen TRL aliquots, in-house controls from pooled plasma, and immunoaffi nity-purifi ed polyclonal antibodies (Meridian Life Sciences, Saco, ME). The relative proportion of apoB within the TRL fraction that was apoB-48 and apoB-100 was assessed by densitometric scanning of 0.1% Coomassie blue R-250-stained SDS-PAGE gels and calculated to be the average of the 14 measurements obtained during the infusion ( 27 ) . b Five of the nine subjects in the torcetrapib 120 mg QD alone group and a sixth subject (who completed the placebo phase but had unsatisfactory enrichment data for the torcetrapib 120 mg QD phase) went on to receive 120 mg of torcetrapib twice daily for an additional 4 weeks. The characteristics of these six subjects did not differ signifi cantly from the entire torcetrapib alone group. c P < 0.01 for comparison with the subjects who did not receive atorvastatin. Effects of torcetrapib on apoB-48 kinetic parameters TRL apoB-48 PS and kinetic parameters at the end of the placebo and torcetrapib phases are presented in Table 3 . In the nonatorvastatin cohort, relative to placebo, torcetrapib 120 mg once daily decreased TRL apoB-48 PS by 49 ± 9% ( P = 0.007), whereas torcetrapib 120 mg twice daily reduced PS by 30 ± 6% ( P = 0.01). Analysis of the kinetic data revealed that the reduction in apoB-48 PS in these subjects was primarily attributable to a torcetrapib-mediated reduction in production. TRL apoB-48 PR was decreased by 49 ± 8% ( P = 0.005) with torcetrapib 120 mg once daily and by 27 ± 17% ( P = 0.13) with torcetrapib 120 mg twice daily. TRL apoB-48 FCR was not altered significantly by either dose of torcetrapib. In the atorvastatin cohort, torcetrapib had no statistically signifi cant effect on TRL apoB-48 PS, FCR, or PR. However, there was considerable interindividual variability in the response to torcetrapib in this cohort, and the data were reanalyzed, omitting one subject with the 3/4 apoE genotype who had marked increases in TRL apoB-48 PS (88%) and PR (39%). Although the percent decrease in PS and PR was greater ( Ϫ 14 ± 10% and Ϫ 19 ± 12%, respectively) when this subject was omitted (data not shown), the torcetrapib-induced effect on TRL apoB-48 kinetic parameters, compared with placebo, remained nonsignifi cant.
As shown in Table 3 , when the nonatorvastatin and atorvastatin cohorts were compared, the nonatorvastatin cohort on placebo had a mean TRL apoB-48 PS of 18.5 ± 4.1 mg, whereas the PS of the atorvastatin cohort was signifi cantly smaller (7.4 ± 1.7 mg; P = 0.03). TRL apoB-48 PR in the atorvastatin cohort on placebo was also signifi cantly lower than that of the nonatorvastatin cohort ( P = 0.04). On torcetrapib, the differences between the two cohorts disappeared (PS: P = 0.64; PR: P = 0.59).
TRL composition and apoB-48 metabolism
In the nonatorvastatin group at the end of the placebo phase, nonfasting plasma TG concentrations were associated with TRL apoB-48 PS ( r = 0.67; P = 0.05), and apoB-48 FCR was associated with TRL apoE FCR ( r = 0.68; P = 0.04). Correlations between the changes in TRL lipid concentrations and apoB-48 kinetic parameters after treatment with torcetrapib alone indicated, as shown in Fig. 2 , that there was a signifi cant relationship between the percent change in nonfasting TRL TG concentration and the percent change in apoB-48 PS ( Fig. 2A : r = 0.92; P = 0.0005) and apoB-48 FCR ( Fig. 2B : r = Ϫ 0.68; P = 0.04), compared with placebo. Overall, subjects with the greatest reduction in TRL TG concentration in response to torcetrapib treatment had the greatest increase in apoB-48 FCR and, thus, had the greatest decrease in apoB-48 PS in response to torcetrapib treatment. Similar associations were observed between the percent change in nonfasting TRL CE concentration and the percent change in apoB-48 PS ( Fig. 2D : r = 0.73; P = 0.02) and apoB-48 FCR ( Fig. 2E : r = Ϫ 0.67; P = 0.05). The associations between the percent change in TRL TG/CE ratio and the percent change in TRL apoB-48 parameters were not signifi cant. In addition, as shown in Fig. 3 , the percent change in apoB-48 PS in response to twice daily cohort, and by 17 ± 9% ( P = 0.06) in the atorvastatin cohort. Changes in TC levels were minimal in all three groups. Plasma TC and TG levels were, as expected, signifi cantly higher in the nonatorvastatin cohort, compared with the levels measured in the atorvastatin cohort, during both the placebo and the torcetrapib phases.
Torcetrapib also reduced lipid concentrations within nonfasting TRL particles ( Table 2 ; see supplementary data for effects on lipoprotein composition). Torcetrapib alone once daily decreased TRL TC by 42 ± 8% ( P < 0.001) relative to placebo, TRL CE by 73 ± 3% ( P < 0.001), and TRL TG by 17 ± 10% ( P = 0.08). The corresponding decreases among subjects who received torcetrapib twice daily were Ϫ 41 ± 7% ( P = 0.004), Ϫ 78 ± 5% ( P = 0.002), and Ϫ 6 ± 9% ( P not signifi cant), respectively. Torcetrapib given in combination with atorvastatin effected signifi cant reductions in TRL TC ( Ϫ 41 ± 8%; P = 0.002) and CE ( Ϫ 69 ± 4%; P < 0.001) and a nonsignifi cant reduction in TRL TG ( Ϫ 16 ± 12%), relative to the levels measured during the placebo phase. The atorvastatin subjects also had signifi cantly lower TRL TC, CE, and TG levels during the placebo (TC: P = 0.003; CE: P = 0.002; TG: P = 0.03) and the torcetrapib phases (TC: P = 0.01; CE: P = 0.02; TG: P = 0.04), compared with the nonatorvastatin once daily subjects, due to the known effects of atorvastatin.
The changes in TRL lipid concentrations in response to torcetrapib treatment translated into striking increases in the TG/CE ratio of TRL particles. Compared with the placebo phase, the TG/CE ratio during the torcetrapib phase increased by 229 ± 31% ( P < 0.001) in the nonatorvastatin 120 mg once daily group, 550 ± 216% ( P = 0.02) in the nonatorvastatin 120 mg twice daily group, and 193 ± 35% ( P = 0.001) in the atorvastatin group. Fig. 1 . Effect of torcetrapib on the nonfasting plasma concentration of TRL apoB-48 in subjects with low HDL cholesterol. Relative to placebo, torcetrapib decreased apoB-48 levels by 49 ± 9% (from 0.47 ± 0.10 to 0.23 ± 0.08 mg/dl) in the torcetrapib 120 mg once daily group (n = 9), by 31 ± 6% (from 0.57 ± 0.15 to 0.40 ± 0.12 mg/dl) in the torcetrapib 120 mg twice daily group (n = 6), and by 2 ± 14% (from 0.19 ± 0.04 to 0.16 ± 0.04 mg/dl) in the atorvastatin group (n = 9). The effects on apoB-100, apoA-I, apoA-II, and apoE are shown in the supplementary data. Data are expressed as mean ± SEM. * P < 0.01 for comparison with the placebo phase. QD, once daily; BID, twice daily. 
DISCUSSION
Interest in CETP inhibition as an effective strategy to reduce coronary heart disease (CHD) risk remains despite the termination of torcetrapib development due to excess all-cause mortality in CHD patients ( 28 ) . There is clear evidence that torcetrapib has off-target, compoundspecifi c effects independent of CETP inhibition (28) (29) (30) that are not associated with other CETP inhibitors, such as anacetrapib ( 31 ) and dalcetrapib ( 32 ), currently being tested in large clinical trials. With this in mind, mechanistic studies conducted with torcetrapib may provide important insight into the effect of CETP inhibition on lipoprotein metabolism.
We have reported previously that torcetrapib-mediated inhibition of CETP markedly reduced plasma concentrations torcetrapib correlated positively with the percent change in TRL apoE PS ( r = 0.75; P = 0.02) and inversely with the percent change in TRL apoE FCR ( r = Ϫ 0.70; P = 0.04). The association between apoB-48 FCR and TRL apoE FCR observed during the placebo phase did not remain after torcetrapib treatment.
In the atorvastatin subjects after torcetrapib treatment, there was a signifi cant relationship between the percent change in nonfasting TRL TG concentration and the percent change in apoB-48 PS ( Fig. 2A : r = 0.87; P = 0.003), compared with placebo, and there was a trend toward signifi cance between the percent change in nonfasting TRL CE levels and the percent change in apoB-48 PS ( Fig. 2D : r = 0.63; P = 0.07). No associations between the percent change in TRL lipids and the percent change in apoB-48 FCR were observed. The percent change in TRL TG concentration and the percent change in apoB-48 PR, compared with placebo, were associated ( Fig. 2C : r = 0.72; P = 0.03); however, when the subject with the 3/4 apoE genotype was omitted from the analysis, the association did not remain ( r = 0.54; P = 0.16). The percent and did not substantially alter plasma lathosterol levels (cholesterol synthesis biomarker) or fecal neutral sterol and bile acid content (16, see supplementary data), suggesting that the rate of reverse cholesterol transport is not compromised. Taken together, these data suggest that apoB-48 secretion may not be affected by torcetrapib through this pathway. There is evidence that CETP inhibition may infl uence enterocyte intracellular lipid metabolism and, hence, apoB-48 production. Niesor et al. (34) demonstrated that after oral dosing of radiolabeled cholesterol, dalcetrapibtreated hamsters had signifi cant increases in plasma HDL cholesterol, accompanied by increases in cholesterol absorption biomarkers, with no change in nonHDL cholesterol. From the data, they hypothesized a preferential increase in the lipidation of nascent HDL by intestinal ATP-binding cassette (ABC) A1. It has also been reported that torcetrapib analogs altered intestinal lipid and lipoprotein processing in rats, reducing the number of chylomicron particles and the proportion of lipids carried by chylomicrons in lymph while increasing the proportion of lipids transported by HDL in lymph ( 35 ) . Whether or not torcetrapib-mediated inhibition of CETP in humans affects the preferential partitioning of intestinal cholesterol to HDL remains to be determined. Regardless of the precise mechanism, decreased availability of lipids for chylomicron particle formation would result in enhanced intracellular degradation of apoB-48 and, thus, less apoB-48 secretion.
During the placebo phase, subjects in the atorvastatin arm of this study had apoB-48 concentrations that were markedly lower than the levels observed in the nonatorvastatin cohort. Studies using oral fat load tests have reported lower apoB-48 and TG concentrations during atorvastatin treatment, compared with placebo, in subjects with hypertriglyceridemia ( 36 ), hypercholesterolemia ( 37 ), familial of TRL particles, small dense LDL, and apoB in subjects with low HDL cholesterol ( 15, 17 ) . These benefi cial effects were associated with signifi cant increases in the catabolism of VLDL apoB-100 and apoE ( 17, 18 ) . In the present study, torcetrapib markedly reduced TRL CE levels, increasing greatly the TG/CE ratio in TRL particles, when the drug was given as monotherapy or in combination with atorvastatin. In contrast, concentrations of TRL apoB-48 were lowered signifi cantly only in the subjects treated with torcetrapib alone. Analysis of the apoB-48 kinetic data revealed that the decrease in apoB-48 concentration in the nonatorvastatin cohort was due to a signifi cant reduction in apoB-48 PR, with no change in the FCR.
Our fi nding of dramatic reductions in TRL CE concentrations is consistent with the concept that the inhibition of CETP activity by torcetrapib markedly decreases the amount of CE transferred from other lipoproteins to TRL. Although a signifi cant fraction of TRL CE in the fasting and the fed state is most likely in the apoB-100-containing TRL particles ( 33 ) , effective inhibition of CETP activity presumably reduces the CE content of apoB-48-containing TRL particles as well, lowering net delivery of TRL CE to the liver. It can be hypothesized that, as a result, biliary cholesterol excretion would probably decrease, less endogenous cholesterol would be available to the intestine for absorption, and lipidation of newly synthesized apoB-48 would be reduced. Plasma sterol markers of cholesterol absorption, which could substantiate this possible mechanism by which apoB-48 production would decrease, were not assessed in this study. However, it has been shown recently in hamsters, an animal model expressing CETP, that torcetrapib had no signifi cant effect on cholesterol absorption or synthesis biomarkers ( 34 ) . This observation concurs with our previous report that, in subjects with low HDL cholesterol, torcetrapib treatment up-regulated hepatic clearance of apoB-100-containing lipoproteins ( 17, 18 ) a Data are presented as mean ± SEM. Signifi cance for comparison of absolute values with placebo phase was determined using a paired t -test on log-transformed data.
b Signifi cance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts on placebo and torcetrapib 120 mg once daily was tested by a two-independent sample t -test. on placebo was signifi cantly lower in the atorvastatin cohort. The atorvastatin subjects on placebo also had substantially lower serum concentrations of lathosterol (reduced cholesterol synthesis) and, in turn, decreased fecal sterol content (16, see supplementary data), parameters associated with chylomicron production. Moreover, atorvastatin therapy in hyperlipidemic men has been shown to stimulate intestinal mRNA expression of the LDL receptor and Niemann-Pick C1Like 1 and to decrease mRNA levels dysbetalipoproteinemia ( 38, 39 ) , and CHD ( 40, 41 ) . The reductions have been associated with enhanced clearance of apoB-48 ( 22 ) and chylomicron-like emulsions ( 42 ) in subjects with dyslipidemia. In subjects with diabetes, Hogue et al. (43) found that atorvastatin reduced TRL apoB-48 concentrations primarily by decreasing its production. In the current study of subjects with low HDL, apoB-48 FCR on placebo was similar in the atorvastatin and the nonatorvastatin cohorts, but the rate of production any of the cohorts. This outcome, which holds even when the statistical analysis controlled for differences in apoE genotype (data not shown), underscores the concept that the effects of torcetrapib on the metabolism of TRL apoB-48-containing particles differ mechanistically from those on TRL apoB-100-containing particles ( 17 ) , despite the presence of apoE, a ligand for hepatic catabolism of both classes of TRL. It is known that TRL apoE is a major determinant of TRL apoB-100 and TRL apoB-48 clearance because these parameters are markedly decreased in human familial apoE defi ciency ( 46 ) . In the present study, the procedure used to isolate TRL from whole plasma did not separate apoB-48-containing particles from apoB-100-containing particles; hence, the torcetrapib-mediated effects on the lipid and apoE content of TRL are infl uenced by alterations in the metabolism not only of apoB-48-containing TRL but also of apoB-100-containing TRL. Based on the associations we did observe, we could speculate that apoEmediated removal of apoB-48-containing lipoproteins is related to the changes in apoE FCR effected by CETP inhibition. Subjects in the nonatorvastatin group with the greatest reduction in apoB-48 PS in response to torcetrapib had the greatest increase in TRL apoE FCR, indicating that the mechanism of chylomicron clearance is consistent with known results. However, enhanced apoEmediated clearance is not the main mechanism by which torcetrapib lowers apoB-48 PS. As discussed above, torcetrapib decreases apoB-48 concentration primarily by decreasing the production rate of apoB-48.
Several limitations are noteworthy. The small number of subjects in each cohort underscores the marked variability in torcetrapib-induced response, especially in the atorvastatin group. The feeding protocol introduces frequent doses of fat into the intestine, which may result in the formation of smaller, less triglyceride-rich apoB-48-containing lipoproteins; however, previous use of the same feeding protocol has demonstrated that both atorvastatin and extended-release niacin treatment enhanced the fractional catabolism of TRL apoB-100 and TRL apoB-48, with no signifi cant change in production ( 22, 25 ) . Measurements of plasma markers of cholesterol absorption, like cholestanol, campesterol, and ␤ -sitosterol, could corroborate the unexpected decrease in apoB-48 production. Further studies to distinguish the effects of CETP inhibition on the metabolism of chylomicronspecifi c lipids and apolipoproteins and to defi ne the molecular mechanism underlying the observed decrease in apoB-48 production are required.
In conclusion, our results provide new insights into the mechanisms by which CETP inhibition attenuates the atherogenic profi le of apoB-48-containing lipoproteins in subjects with low HDL cholesterol. These data indicate that torcetrapib reduces apoB-48 levels by decreasing production of apoB-48. Adding torcetrapib treatment to atorvastatin therapy had no further benefi t on apoB-48 concentrations already lowered by atorvastatin. This alteration in apoB-48 metabolism may be another mechanism by which CETP inhibition contributes to the reduction of CHD risk in humans. of ABCG5 and ABCG8, without changing signifi cantly the expression of apoB-48 ( 44 ) . There is, however, a great deal of individual variability in these studies, and the precise effect that statin therapy has on apoB-48 metabolism may depend on the underlying lipoprotein disorder. In addition, the present study was not designed to examine the effect of atorvastatin on apoB-48 metabolism, but only that of torcetrapib on this parameter, in subjects either untreated or on atorvastatin at baseline.
Overall, the data indicate that, in contrast to torcetrapib monotherapy, torcetrapib added to atorvastatin had no signifi cant effect on plasma apoB-48 levels. Our results agree with those of Guerin and colleagues ( 45 ) , who have reported that torcetrapib 60 mg once daily in combination with atorvastatin 10 mg once daily had only a minor effect on chylomicron levels. In our view, the one signifi cant effect of adding torcetrapib to atorvastatin therapy was the marked reduction in TRL CE concentration.
In the nonatorvastatin subjects, the percent increase in apoB-48 FCR in response to torcetrapib was a strong predictor of the torcetrapib-mediated percent decrease in TRL TG and TRL CE levels. Torcetrapib treatment, however, did not enhance the overall catabolism of apoB-48 in Supplemental Material can be found at:
